Your browser doesn't support javascript.
loading
Ibrutinib-induced severe liver injury.
Nandikolla, Amara G; Derman, Olga; Nautsch, Deborah; Liu, Qiang; Massoumi, Hatef; Venugopal, Sangeetha; Braunschweig, Ira; Janakiram, Murali.
Afiliação
  • Nandikolla AG; Department of Oncology Montefiore Medical Center/Albert Einstein College of Medicine Bronx New York USA.
  • Derman O; Department of Oncology Montefiore Medical Center/Albert Einstein College of Medicine Bronx New York USA.
  • Nautsch D; Department of Pathology Montefiore Medical Center/Albert Einstein College of Medicine Bronx New York USA.
  • Liu Q; Department of Pathology Montefiore Medical Center/Albert Einstein College of Medicine Bronx New York USA.
  • Massoumi H; Department of Hepatology Montefiore Medical Center/Albert Einstein College of Medicine Bronx New York USA.
  • Venugopal S; Department of Medicine Montefiore Medical Center Bronx New York USA.
  • Braunschweig I; Department of Oncology Montefiore Medical Center/Albert Einstein College of Medicine Bronx New York USA.
  • Janakiram M; Department of Oncology Montefiore Medical Center/Albert Einstein College of Medicine Bronx New York USA.
Clin Case Rep ; 5(6): 735-738, 2017 06.
Article em En | MEDLINE | ID: mdl-28588800
Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B-cell receptor pathway, is an effective therapeutic agent for B-cell lymphomas. As these drugs are novel, long-term or rare adverse events are not yet known. We report the first case of ibrutinib-induced severe liver injury in a patient with relapsed/refractory CLL.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Case Rep Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Case Rep Ano de publicação: 2017 Tipo de documento: Article